<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877613</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 848848; UPCC# 12320</org_study_id>
    <nct_id>NCT04877613</nct_id>
  </id_info>
  <brief_title>GFRα4 CAR T Cells in MTC Patients</brief_title>
  <official_title>Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase 1 study to assess the safety and feasibility of autologous T&#xD;
      cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB&#xD;
      (TCRζ/4-1BB) co-stimulatory domains (referred to as &quot;CART-GFRa4 cells&quot;) in patients with&#xD;
      incurable medullary thyroid cancer (MTC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2039</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2039</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The is a Phase I dose finding study to determine the safety of CART-GFRa4 cells. Dose escalation and determination of maximum tolerated dose (MTD) will be based on the standard 3+3 design to explore 3 possible dose levels.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0.</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of manufacturing products that meet release criteria.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who have a response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Metastatic Medullary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of CART-GFRa4 cells</intervention_name>
    <description>Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.</description>
    <arm_group_label>Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lyphodepletion</description>
    <arm_group_label>Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lyphodepletion</description>
    <arm_group_label>Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
    <arm_group_label>Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed, written informed consent&#xD;
&#xD;
          2. Male or female age ≥ 18 years&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of medullary thyroid cancer (MTC).&#xD;
&#xD;
          4. Incurable recurrent/metastatic disease that is progressive after at least 1 prior&#xD;
             tyrosine kinase inhibitor (TKI) containing regimen, or the patient was intolerant of&#xD;
             or declined such therapy.&#xD;
&#xD;
          5. Adequate organ function defined as:&#xD;
&#xD;
               1. Serum creatinine ≤ 2.5 mg/dl or estimated creatinine clearance ≥ 30 ml/min and&#xD;
                  not on dialysis.&#xD;
&#xD;
               2. AST ≤ 5x upper limit of normal range and total bilirubin ≤ 2.0 mg/dl; except for&#xD;
                  patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome.&#xD;
&#xD;
               3. Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA&#xD;
&#xD;
               4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and&#xD;
                  pulse oxygen &gt; 92% on room air&#xD;
&#xD;
          6. ECOG Performance Status that is either 0 or 1.&#xD;
&#xD;
          7. Toxicities from prior therapies must have recovered to grade ≤ 2 according to the&#xD;
             CTCAE 5.0 criteria or to the patient's prior baseline.&#xD;
&#xD;
          8. Patients must have evaluable disease as defined by RECIST 1.1.&#xD;
&#xD;
          9. Subjects of reproductive potential must agree to use acceptable birth control methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          2. Any other active, uncontrolled infection.&#xD;
&#xD;
          3. Any prior history of moderate to severe (Grade 2 or higher) pneumonitis.&#xD;
&#xD;
          4. Subjects with chronic kidney disease with Grade 2 or higher renal impairment (eGFR or&#xD;
             CrCl 59-30 ml/min/1.73 m2).&#xD;
&#xD;
          5. Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification.&#xD;
&#xD;
          6. Clinically apparent arrhythmia or arrhythmias that are not stable on medical&#xD;
             management within two weeks of physician-investigator confirmation of eligibility.&#xD;
&#xD;
          7. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be&#xD;
             on a stable low dose of steroids (≤10mg equivalent of prednisone). Use of inhaled&#xD;
             steroids is allowable. Corticosteroid treatment as anti-emetic prophylaxis on the day&#xD;
             of lymphodepleting chemotherapy administration is allowed per institutional practice.&#xD;
&#xD;
          8. Any moderate to severe skin rash or allergies requiring systemic treatment.&#xD;
&#xD;
          9. Receipt of immune checkpoint inhibitors within 2 months prior to&#xD;
             physician-investigator confirmation of eligibility.&#xD;
&#xD;
         10. Pregnant or nursing (lactating) women.&#xD;
&#xD;
         11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to&#xD;
             ≥ 10mg daily of prednisone. Patients with autoimmune neurological diseases (such as MS&#xD;
             or Parkinson's) will be excluded.&#xD;
&#xD;
         12. Have any history of prior or active central nervous system (CNS) involvement (e.g.,&#xD;
             leptomeningeal disease, parenchymal masses) with MTC. Screening for this (e.g., with&#xD;
             lumbar puncture and/or brain MRI) is not required unless suspicious symptoms and/or&#xD;
             radiographic findings are present. Subjects with calvarial metastatic disease that&#xD;
             extends intracranially and involves the dura will be excluded, even if CSF is negative&#xD;
             for MTC.&#xD;
&#xD;
         13. Known seizure disorder or history of prior seizures requiring medication.&#xD;
&#xD;
         14. History of allergy or hypersensitivity to study product excipients (human serum&#xD;
             albumin, DMSO, and Dextran 40).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abramson Cancer Center Clinical Trials Service</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abramson Cancer Center Clinical Trials Service</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

